z-logo
open-access-imgOpen Access
Genetic Testing Contributes to Diagnosis in Cerebral Palsy: Aicardi-Goutières Syndrome as an Example
Author(s) -
Diane Beysen,
Chania De Cordt,
Charlotte Dielman,
Benson Ogunjimi,
Julie Dandelooy,
Edwin Reyniers,
Katrien Janssens,
Marije M.E. Meuwissen
Publication year - 2021
Publication title -
frontiers in neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.23
H-Index - 67
ISSN - 1664-2295
DOI - 10.3389/fneur.2021.617813
Subject(s) - cerebral palsy , etiology , medicine , genetic testing , epilepsy , intellectual disability , pediatrics , genetic heterogeneity , neurodevelopmental disorder , spastic quadriplegia , spastic , phenotype , pathology , psychiatry , genetics , autism , gene , biology
Cerebral palsy (CP) is a non-progressive neurodevelopmental disorder characterized by motor impairments, often accompanied by co-morbidities such as intellectual disability, epilepsy, visual and hearing impairment and speech and language deficits. Despite the established role of hypoxic–ischemic injury in some CP cases, several studies suggest that birth asphyxia is actually an uncommon cause, accounting for <10% of CP cases. For children with CP in the absence of traditional risk factors, a genetic basis to their condition is increasingly suspected. Several recent studies indeed confirm copy number variants and single gene mutations with large genetic heterogeneity as an etiology in children with CP. Here, we report three patients with spastic cerebral palsy and a genetically confirmed diagnosis of Aicardi-Goutières syndrome (AGS), with highly variable phenotypes ranging from clinically suggestive to non-specific symptomatology. Our findings suggest that AGS may be a rather common cause of CP, that frequently remains undiagnosed without additional genetic testing, as in only one case a clinical suspicion of AGS was raised. Our data show that a diagnosis of AGS must be considered in cases with spastic CP, even in the absence of characteristic brain abnormalities. Importantly, a genetic diagnosis of AGS may have significant therapeutic consequences, as targeted therapies are being developed for type 1 interferonopathies, the group of diseases to which AGS belongs. Our findings demonstrate the importance of next generation sequencing in CP patients without an identifiable cause, since targeted diagnostic testing is hampered by the often non-specific presentation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom